



## Trupanion Reports Second Quarter 2021 Results

SEATTLE, WA. August 5, 2021-- [Trupanion](#), Inc. (Nasdaq: TRUP), the leading provider of medical insurance for cats and dogs, today announced financial results for the second quarter ended June 30, 2021.

“Q2 was another great quarter with net pet growth up 60% year-over-year, led by exceptionally strong retention rates,” said Darryl Rawlings, founder and chief executive officer of Trupanion.


### Second Quarter 2021 Financial and Business Highlights

- Total revenue was \$168.3 million, an increase of 43% compared to the second quarter of 2020.
- Total enrolled pets (including pets from our other business segment) was 1,024,226 at June 30, 2021, an increase of 38% over the second quarter of 2020.
- Subscription business revenue was \$120.4 million, an increase of 30% compared to the second quarter of 2020 (27% on a constant currency basis).
- Subscription enrolled pets was 643,395 at June 30, 2021, an increase of 22% over the second quarter of 2020.
- Net loss was \$(9.2) million, or \$(0.23) per basic and diluted share, compared to net income of \$1.4 million, or \$0.04 per basic and diluted share, in the second quarter of 2020. Net loss per share was impacted by \$0.11 due to an increase in stock-based compensation and by \$0.04 due to an increase in depreciation and amortization when compared to the prior year period. The remaining year-over-year change in earnings per share primarily reflects our accelerated growth and associated acquisition spend in the second quarter of 2021.
- Adjusted EBITDA was \$0.2 million, compared to adjusted EBITDA of \$5.5 million in the second quarter of 2020.
- Operating cash flow was \$(2.2) million and free cash flow was \$(5.1) million in the second quarter of 2021. This compared to operating cash flow of \$4.9 million and free cash flow of \$3.1 million in the second quarter of 2020.

### First Half 2021 Financial and Business Highlights

- Total revenue was \$322.9 million, an increase of 41% compared to the first half of 2020.
- Subscription business revenue was \$233.7 million, an increase of 28% compared to the first half of 2020.
- Net loss was \$(21.7) million, or \$(0.54) per basic and diluted share, compared to net income of \$0.2 million, or \$0.01 per basic and diluted share, in the first half of 2020. Net loss per share was impacted by \$0.28 due to an increase in stock-based compensation and by \$0.08 due to an increase in depreciation and amortization when compared to the prior year period. The remaining year-over-year change in earnings per share primarily reflects our accelerated growth and associated acquisition spend in the first half of 2021.
- Adjusted EBITDA was \$(0.9) million, compared to adjusted EBITDA of \$7.5 million in the first half of 2020.
- Operating cash flow was \$(3.9) million and free cash flow was \$(9.7) million in the first half of 2021. This compared to operating cash flow of \$7.8 million and free cash flow of \$4.5 million in the first half of 2020.

## Revenue by Quarter



## Conference Call

Trupanion's management will host a conference call today to review its second quarter 2021 results. The call is scheduled to begin shortly after 1:30 p.m. PT/ 4:30 p.m. ET. A live webcast will be accessible through the Investor Relations section of Trupanion's website at <http://investors.trupanion.com> and will be archived online for 3 months upon completion of the conference call. Participants can access the conference call by dialing 1-877-407-0784 (United States) or 1-201-689-8560 (International). A telephonic replay of the call will also be available after the completion of the call, by dialing 1-844-512-2921 (United States) or 1-412-317-6671 (International) and entering the replay pin number: 13720129.

## About Trupanion

Trupanion is a leader in medical insurance for cats and dogs throughout the United States, Canada and Australia with over 600,000 pets enrolled. For over two decades, Trupanion has given pet owners peace of mind so they can focus on their pet's recovery, not financial stress. Trupanion is committed to providing pet owners with the highest value in pet medical insurance with unlimited payouts for the life of their pets. With its proprietary software, Trupanion is the only provider with the technology to pay veterinarians directly in minutes at the time of checkout. Trupanion is listed on NASDAQ under the symbol "TRUP". The company was founded in 2000 and is headquartered in Seattle, WA. Trupanion policies are issued, in the United States, by its wholly-owned insurance entity American Pet Insurance Company and, in Canada, by Omega General Insurance Company. Trupanion Australia is a partnership between Trupanion and Hollard Insurance Company. For more information, please visit [trupanion.com](http://trupanion.com).

## Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 relating to, among other things, expectations, plans, prospects and financial results for Trupanion, including, but not limited to, its expectations regarding its ability to continue to grow its enrollments and revenue, implement its alliance with Aflac and otherwise execute its business plan. These forward-looking statements are based upon the current expectations and beliefs of Trupanion's management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements made in this press release are based on information available to Trupanion as of the date hereof, and Trupanion has no obligation to update these forward-looking statements.

In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the ability to achieve or maintain profitability and/or appropriate levels of cash flow in future periods; the ability to keep growing our membership base and revenue; the accuracy of assumptions used in determining appropriate member acquisition expenditures; the severity and frequency of claims; the ability to maintain high retention rates; the accuracy of assumptions used in pricing medical plan subscriptions and the ability to accurately estimate the impact of new products or offerings on claims frequency; actual claims expense exceeding estimates; regulatory and other constraints on the ability to institute, or the decision to otherwise delay, pricing modifications in response to changes in actual or estimated claims expense; the effectiveness and statutory or regulatory compliance of our Territory Partner model and of our Territory Partners, veterinarians and other third parties in recommending medical plan subscriptions to potential members; the ability to retain existing Territory Partners and increase the number of Territory Partners and active hospitals; compliance by us and those referring us members with laws and regulations that apply to our business, including the sale of a pet medical plan; the ability to maintain the security of our data; fluctuations in the Canadian currency exchange rate; the ability to protect our proprietary and member information; the ability to maintain our culture and team; the ability to maintain the requisite amount of risk-based capital; our ability to implement and maintain effective controls, including over financial reporting; the ability to protect and enforce Trupanion's intellectual property rights; the ability to successfully implement our alliance with Aflac; the ability to continue key contractual relationships with third parties; third-party claims including litigation and regulatory actions; the ability to recognize benefits from investments in new solutions and enhancements to Trupanion's technology platform and website; and our ability to retain key personnel.

For a detailed discussion of these and other cautionary statements, please refer to the risk factors discussed in filings with the Securities and Exchange Commission (SEC), including but not limited to, Trupanion's Annual Report on Form 10-K for the year ended December 31, 2020 and any subsequently filed reports on Forms 10-Q and 8-K. All documents are available through the SEC's Electronic Data Gathering Analysis and Retrieval system at [www.sec.gov](http://www.sec.gov) or the Investor Relations section of Trupanion's website at <http://investors.trupanion.com>.

### **Non-GAAP Financial Measures**

Trupanion's stated results may include certain non-GAAP financial measures. These non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in its industry as other companies in its industry may calculate or use non-GAAP financial measures differently. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on Trupanion's reported financial results. The presentation and utilization of non-GAAP financial measures is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP. Trupanion urges its investors to review the reconciliation of its non-GAAP financial measures to the most directly comparable GAAP financial measures in its consolidated financial statements, and not to rely on any single financial or operating measure to evaluate its business. These reconciliations are included below and on [Trupanion's Investor Relations website](#).

Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company's non-cash expenses, Trupanion believes that providing various non-GAAP financial measures that exclude stock-based compensation expense and depreciation and amortization expense allows for more meaningful comparisons between its operating results from period to period. Trupanion offsets sales and marketing expense with sign-up fee revenue in the calculation of net acquisition cost because it collects sign-up fee revenue from new members at the time of enrollment and considers it to be an offset to a portion of Trupanion's sales and marketing expenses. Trupanion believes this allows it to calculate and present financial measures in a consistent manner across

periods. Trupanion's management believes that the non-GAAP financial measures and the related financial measures derived from them are important tools for financial and operational decision-making and for evaluating operating results over different periods of time.

**Trupanion, Inc.**  
**Consolidated Statements of Operations**  
(in thousands, except share data)

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2021</b>	<b>2020</b>	<b>2021</b>	<b>2020</b>
	<i>(unaudited)</i>			
<b>Revenue:</b>				
Subscription business	\$ 120,373	\$ 92,453	\$ 233,665	\$ 181,937
Other business	47,887	25,467	89,280	47,284
Total revenue	168,260	117,920	322,945	229,221
<b>Cost of revenue:</b>				
Subscription business <sup>(1)</sup>	99,746	74,594	195,283	148,016
Other business	43,969	23,459	82,017	43,486
Total cost of revenue <sup>(2)</sup>	143,715	98,053	277,300	191,502
<b>Operating expenses:</b>				
Technology and development <sup>(1)</sup>	4,079	2,293	7,810	4,413
General and administrative <sup>(1)</sup>	7,435	5,073	14,651	9,933
Sales and marketing <sup>(1)</sup>	19,390	9,242	39,094	19,684
Depreciation and amortization <sup>(3)</sup>	3,158	1,723	6,251	3,104
Total operating expenses	34,062	18,331	67,806	37,134
Gain (loss) from investment in joint venture	5	(27)	(80)	(86)
Operating income (loss)	(9,512)	1,509	(22,241)	499
Interest expense	3	341	1	720
Other income, net	(99)	(202)	(161)	(484)
Gain (loss) before income taxes	(9,416)	1,370	(22,081)	263
Income tax expense (benefit)	(195)	17	(412)	43
Net income (loss)	\$ (9,221)	\$ 1,353	\$ (21,669)	\$ 220
<b>Net income (loss) per share:</b>				
Basic	\$ (0.23)	\$ 0.04	\$ (0.54)	\$ 0.01
Diluted	\$ (0.23)	\$ 0.04	\$ (0.54)	\$ 0.01
<b>Weighted average shares of common stock outstanding:</b>				
Basic	40,142,872	35,143,592	39,922,885	35,075,322
Diluted	40,142,872	36,688,167	39,922,885	36,601,927

<sup>(1)</sup>Includes stock-based compensation expense as follows:

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2021</b>	<b>2020</b>	<b>2021</b>	<b>2020</b>
Cost of revenue	\$ 1,224	\$ 344	\$ 4,458	\$ 612
Technology and development	800	133	1,464	233
General and administrative	2,322	1,075	4,141	1,804
Sales and marketing	2,181	675	4,912	1,231
Total stock-based compensation expense	\$ 6,527	\$ 2,227	\$ 14,975	\$ 3,880

<sup>(2)</sup>The breakout of cost of revenue between veterinary invoice expense and other cost of revenue is as follows:

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2021</b>	<b>2020</b>	<b>2021</b>	<b>2020</b>
Veterinary invoice expense	\$ 118,282	\$ 82,049	\$ 228,152	\$ 161,689
Other cost of revenue	25,433	16,004	49,148	29,813
Total cost of revenue	\$ 143,715	\$ 98,053	\$ 277,300	\$ 191,502

<sup>(3)</sup>Depreciation and amortization expenses have been reclassified as a separate line item and prior period amounts have been reclassified from their original presentation to conform to the current period presentation. The Company has elected to present depreciation and amortization expenses as a separate line to better align with management's view of the Company's operating results.

**Trupanion, Inc.**  
**Consolidated Balance Sheets**  
(in thousands, except share data)

	<u>June 30, 2021</u>	<u>December 31, 2020</u>
	<i>(unaudited)</i>	
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 117,332	\$ 139,878
Short-term investments	102,089	89,862
Accounts and other receivables	139,966	99,065
Prepaid expenses and other assets	10,535	8,222
Total current assets	<u>369,922</u>	<u>337,027</u>
Restricted cash	6,322	6,319
Long-term investments, at fair value	6,226	5,566
Property and equipment, net	74,405	72,602
Intangible assets, net	25,120	27,134
Other long-term assets	16,476	16,557
Goodwill	33,495	33,045
Total assets	<u>\$ 531,966</u>	<u>\$ 498,250</u>
<b>Liabilities and stockholders' equity</b>		
Current liabilities:		
Accounts payable	\$ 4,863	\$ 6,059
Accrued liabilities and other current liabilities	22,530	22,864
Reserve for veterinary invoices	35,856	28,929
Deferred revenue	126,614	92,547
Total current liabilities	<u>189,863</u>	<u>150,399</u>
Deferred tax liabilities	4,259	4,705
Other liabilities	3,639	3,207
Total liabilities	<u>197,761</u>	<u>158,311</u>
Stockholders' equity:		
Common stock: \$0.00001 par value per share, 100,000,000 shares authorized; 41,164,220 and 40,231,055 issued and outstanding at June 30, 2021; 40,383,972 and 39,450,807 shares issued and outstanding at December 31, 2020	—	—
Preferred stock: \$0.00001 par value per share, 10,000,000 shares authorized; no shares issued and outstanding	—	—
Additional paid-in capital	453,950	439,007
Accumulated other comprehensive loss	4,063	3,071
Accumulated deficit	(113,029)	(91,360)
Treasury stock, at cost: 933,165 shares at June 30, 2021 and 933,165 shares at December 31, 2020	(10,779)	(10,779)
Total stockholders' equity	<u>334,205</u>	<u>339,939</u>
Total liabilities and stockholders' equity	<u>\$ 531,966</u>	<u>\$ 498,250</u>

**Trupanion, Inc.**  
**Consolidated Statements of Cash Flows**  
(in thousands)

	<u>Three Months Ended June 30,</u>		<u>Six Months Ended June 30,</u>	
	<u>2021</u>	<u>2020</u>	<u>2021</u>	<u>2020</u>
	<i>(unaudited)</i>			
<b>Operating activities</b>				
Net (loss) income	\$ (9,221)	\$ 1,353	\$ (21,669)	\$ 220
Adjustments to reconcile net (loss) income to cash provided by operating activities:				
Depreciation and amortization	3,158	1,723	6,251	3,104
Stock-based compensation expense	6,527	2,227	14,975	3,880
Other, net	(315)	29	(545)	102
Changes in operating assets and liabilities:				
Accounts and other receivables	(21,991)	(14,405)	(40,796)	(26,102)
Prepaid expenses and other assets	(761)	(249)	(2,092)	(444)
Accounts payable, accrued liabilities, and other liabilities	(907)	(806)	(872)	516
Reserve for veterinary invoices	5,691	1,439	6,870	3,264
Deferred revenue	15,632	13,539	33,956	23,234
Net cash (used in) provided by operating activities	(2,187)	4,850	(3,922)	7,774
<b>Investing activities</b>				
Purchases of investment securities	(31,216)	(14,971)	(43,373)	(26,550)
Maturities of investment securities	20,102	15,704	30,580	20,804
Purchases of property, equipment and intangible assets	(2,887)	(1,743)	(5,770)	(3,239)
Other	(33)	98	(73)	107
Net cash used in investing activities	(14,034)	(912)	(18,636)	(8,878)
<b>Financing activities</b>				
Proceeds from exercise of stock options	1,120	1,108	2,358	1,667
Shares withheld to satisfy tax withholding	(870)	(120)	(2,751)	(441)
Borrowings from line of credit, net of financing fees	—	(9)	—	3,735
Repayments to line of credit	—	(2,500)	—	(2,500)
Other financing	—	—	—	(78)
Net cash provided by (used in) financing activities	250	(1,521)	(393)	2,383
Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash, net	178	375	408	(434)
Net change in cash, cash equivalents, and restricted cash	(15,793)	2,792	(22,543)	845
Cash, cash equivalents, and restricted cash at beginning of period	139,447	28,621	146,197	30,568
Cash, cash equivalents, and restricted cash at end of period	<u>\$ 123,654</u>	<u>\$ 31,413</u>	<u>\$ 123,654</u>	<u>\$ 31,413</u>

The following tables set forth our key operating metrics:

	<b>Six Months Ended June 30,</b>	
	<b>2021</b>	<b>2020</b>
<b>Total Business:</b>		
Total pets enrolled (at period end)	1,024,226	744,727
<b>Subscription Business:</b>		
Total subscription pets enrolled (at period end)	643,395	529,400
Monthly average revenue per pet	\$ 63.34	\$ 59.19
Lifetime value of a pet, including fixed expenses	\$ 681	\$ 597
Average pet acquisition cost (PAC)	\$ 281	\$ 222
Average monthly retention	98.72 %	98.66 %

	<b>Three Months Ended</b>							
	<b>June. 30, 2021</b>	<b>Mar. 31, 2021</b>	<b>Dec. 31, 2020</b>	<b>Sept. 30, 2020</b>	<b>Jun. 30, 2020</b>	<b>Mar. 31, 2020</b>	<b>Dec. 31, 2019</b>	<b>Sept. 30, 2019</b>
<b>Total Business:</b>								
Total pets enrolled (at period end)	1,024,226	943,854	862,928	804,251	744,727	687,435	646,728	613,694
<b>Subscription Business:</b>								
Total subscription pets enrolled (at period end)	643,395	609,835	577,957	552,909	529,400	508,480	494,026	479,427
Monthly average revenue per pet	\$ 63.69	\$ 62.97	\$ 62.03	\$ 60.87	\$ 59.40	\$ 58.96	\$ 58.58	\$ 58.12
Lifetime value of a pet, including fixed expenses	\$ 681	\$ 684	\$ 653	\$ 615	\$ 597	\$ 535	\$ 523	\$ 511
Average pet acquisition cost (PAC)	\$ 284	\$ 279	\$ 272	\$ 261	\$ 199	\$ 247	\$ 222	\$ 208
Average monthly retention	98.72 %	98.73 %	98.71 %	98.69 %	98.66 %	98.59 %	98.58 %	98.59 %

The following table reflects the reconciliation of cash provided by operating activities to free cash flow (in thousands):

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2021</b>	<b>2020</b>	<b>2021</b>	<b>2020</b>
Net cash (used in) provided by operating activities	\$ (2,187)	\$ 4,850	\$ (3,922)	\$ 7,774
Purchases of property and equipment	(2,887)	(1,743)	(5,770)	(3,239)
Free cash flow	\$ (5,074)	\$ 3,107	\$ (9,692)	\$ 4,535



The following table reflects the reconciliation between GAAP and non-GAAP measures (in thousands except percentages):

	<b>Three Months Ended June</b>		<b>Six Months Ended June 30,</b>	
	<b>2021</b>	<b>2020</b>	<b>2021</b>	<b>2020</b>
Veterinary invoice expense	\$ 118,282	\$ 82,049	\$ 228,152	\$ 161,689
Excluding:				
Stock-based compensation expense	(672)	(245)	(2,971)	(423)
Other business cost of paying veterinary invoices	(31,029)	(16,019)	(57,173)	(30,471)
<b>Subscription cost of paying veterinary invoices</b>	<b>\$ 86,581</b>	<b>\$ 65,785</b>	<b>\$ 168,008</b>	<b>\$ 130,795</b>
% of subscription revenue	71.9 %	71.2 %	71.9 %	71.9 %
Other cost of revenue	\$ 25,433	\$ 16,004	\$ 49,148	\$ 29,813
Excluding:				
Stock-based compensation expense	(552)	(99)	(1,487)	(189)
Other business variable expenses	(12,940)	(7,440)	(24,844)	(13,015)
<b>Subscription variable expenses</b>	<b>\$ 11,941</b>	<b>\$ 8,465</b>	<b>\$ 22,817</b>	<b>\$ 16,609</b>
% of subscription revenue	9.9 %	9.2 %	9.8 %	9.1 %
Technology and development expense	\$ 4,079	\$ 2,293	\$ 7,810	\$ 4,413
General and administrative expense	7,435	5,073	14,651	9,933
Excluding:				
Stock-based compensation expense	(3,122)	(1,208)	(5,605)	(2,037)
Development expenses <sup>1</sup>	(1,121)	—	(1,942)	—
Business combination transaction costs <sup>2</sup>	—	—	(82)	—
<b>Fixed expenses</b>	<b>\$ 7,271</b>	<b>\$ 6,158</b>	<b>\$ 14,832</b>	<b>\$ 12,309</b>
% of total revenue	4.3 %	5.2 %	4.6 %	5.4 %
Sales and marketing expense	\$ 19,390	\$ 9,242	\$ 39,094	\$ 19,684
Excluding:				
Stock-based compensation expense	(2,181)	(675)	(4,912)	(1,231)
Other business acquisition cost	(118)	(191)	(289)	(354)
<b>Subscription acquisition cost</b>	<b>\$ 17,091</b>	<b>\$ 8,376</b>	<b>\$ 33,893</b>	<b>\$ 18,099</b>
% of subscription revenue	14.2 %	9.1 %	14.5 %	10.0 %
Technology and development	\$ 4,079	\$ 2,293	\$ 7,810	\$ 4,413
Excluding:				
Stock-based compensation expense	(800)	(133)	(1,464)	(233)
Technology expenses	(2,158)	(2,160)	(4,404)	(4,180)
<b>Development expenses<sup>1</sup></b>	<b>\$ 1,121</b>	<b>\$ —</b>	<b>\$ 1,942</b>	<b>\$ —</b>
% of total revenue	0.7 %	— %	0.6 %	— %

<sup>1</sup>As we enter the next phase of our growth, we expect to invest in initiatives that are pre-revenue, including adding new products and international expansion. These development expenses are costs related to product exploration and development that are pre-revenue and historically have been insignificant. We view these activities as uses of our adjusted operating income separate from net acquisition spend.

<sup>2</sup>These one-time expenses related to our acquisition of a software business, primarily related to legal and transaction costs incurred.

The following tables reflect the reconciliation of acquisition cost and net acquisition cost to sales and marketing expense (in thousands):

	<b>Six Months Ended June 30,</b>	
	<b>2021</b>	<b>2020</b>
Sales and marketing expenses	\$ 39,094	\$ 19,684
Excluding:		
Stock-based compensation expense	(4,912)	(1,231)
Acquisition cost	34,182	18,453
Net of:		
Sign-up fee revenue	(2,524)	(1,546)
Other business segment sales and marketing expense	(289)	(354)
Net acquisition cost	<u>\$ 31,369</u>	<u>\$ 16,553</u>

	<b>Three Months Ended</b>							
	<b>June. 30, 2021</b>	<b>Mar. 31, 2021</b>	<b>Dec. 31, 2020</b>	<b>Sept. 30, 2020</b>	<b>Jun. 30, 2020</b>	<b>Mar. 31, 2020</b>	<b>Dec. 31, 2019</b>	<b>Sept. 30, 2019</b>
Sales and marketing expenses	\$ 19,390	\$ 19,704	\$ 14,809	\$ 13,344	\$ 9,242	\$ 10,442	\$ 9,212	\$ 9,255
Excluding:								
Stock-based compensation expense	(2,181)	(2,731)	(801)	(741)	(675)	(556)	(547)	(577)
Acquisition cost	17,209	16,973	14,008	12,603	8,567	9,886	8,665	8,678
Net of:								
Sign-up fee revenue	(1,260)	(1,264)	(919)	(827)	(781)	(765)	(730)	(790)
Other business segment sales and marketing expense	(118)	(171)	(201)	(265)	(191)	(163)	(152)	(94)
Net acquisition cost	<u>\$ 15,831</u>	<u>\$ 15,538</u>	<u>\$ 12,888</u>	<u>\$ 11,511</u>	<u>\$ 7,595</u>	<u>\$ 8,958</u>	<u>\$ 7,783</u>	<u>\$ 7,794</u>

The following tables reflect the reconciliation of adjusted EBITDA to net income (loss) (in thousands):

	<b>Six Months Ended June 30,</b>	
	<b>2021</b>	<b>2020</b>
Net (loss) income	\$(21,669)	\$ 220
Excluding:		
Stock-based compensation expense	14,975	3,880
Depreciation and amortization expense	6,251	3,104
Interest income	(172)	(471)
Interest expense	1	720
Other non-operating expenses	3	96
Income tax (benefit) expense	(412)	43
Business combination transaction costs	82	—
Loss (gain) from equity method investment	6	(117)
Adjusted EBITDA	<u>\$ (935)</u>	<u>\$ 7,475</u>

	<b>Three Months Ended</b>							
	<b>June 30, 2021</b>	<b>Mar. 31, 2021</b>	<b>Dec. 31, 2020</b>	<b>Sept. 30, 2020</b>	<b>Jun. 30, 2020</b>	<b>Mar. 31, 2020</b>	<b>Dec. 31, 2019</b>	<b>Sept. 30, 2019</b>
Net (loss) income	\$ (9,221)	\$(12,448)	\$ (3,502)	\$ (2,558)	\$ 1,353	\$ (1,133)	\$ 636	\$ 782
Excluding:								
Stock-based compensation expense	6,527	8,448	2,602	2,430	2,227	1,653	1,771	1,845
Depreciation and amortization expense	3,158	3,093	2,301	1,666	1,723	1,381	1,274	1,181
Interest income	(84)	(88)	(83)	(74)	(134)	(337)	(516)	(411)
Interest expense	3	(2)	337	324	341	379	375	340
Other non-operating expenses	3	—	1	2	44	52	(22)	122
Income tax (benefit) expense	(195)	(217)	44	26	17	26	157	18
Business combination transaction costs	—	82	522	—	—	—	—	—
Loss (gain) from equity method investment	6	—	—	—	(117)	—	—	—
Adjusted EBITDA	<u>\$ 197</u>	<u>\$ (1,132)</u>	<u>\$ 2,222</u>	<u>\$ 1,816</u>	<u>\$ 5,454</u>	<u>\$ 2,021</u>	<u>\$ 3,675</u>	<u>\$ 3,877</u>

**Contacts:**

**Investors:**

Laura Bainbridge, Vice President, Corporate Communications

206.607.1929

[InvestorRelations@trupanion.com](mailto:InvestorRelations@trupanion.com)